Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Common Equity: 2010-2025

Historic Common Equity for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to $702.3 million.

  • Iovance Biotherapeutics' Common Equity fell 9.20% to $702.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $702.3 million, marking a year-over-year decrease of 9.20%. This contributed to the annual value of $710.4 million for FY2024, which is 21.52% up from last year.
  • As of Q3 2025, Iovance Biotherapeutics' Common Equity stood at $702.3 million, which was up 0.54% from $698.5 million recorded in Q2 2025.
  • Iovance Biotherapeutics' 5-year Common Equity high stood at $773.5 million for Q3 2024, and its period low was $578.6 million during Q2 2023.
  • In the last 3 years, Iovance Biotherapeutics' Common Equity had a median value of $698.5 million in 2025 and averaged $691.4 million.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 32.83% in 2024, then fell by 9.20% in 2025.
  • Iovance Biotherapeutics' Common Equity (Quarterly) stood at $584.6 million in 2023, then climbed by 21.52% to $710.4 million in 2024, then fell by 9.20% to $702.3 million in 2025.
  • Its Common Equity stands at $702.3 million for Q3 2025, versus $698.5 million for Q2 2025 and $767.9 million for Q1 2025.